In both test cohort and validation cohort, HCC patients with both high expression of LASS2 and TGF-β1 had the most favorable OS and TTR rates, whereas those patients with both low expression of LASS2 and TGF-β1 had the poorest OS and TTR rates. The gene discussed is CERS2; the disease is hepatocellular carcinoma.